Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that on July 7, 2020, it was issued a patent (US10,702,495) by the United States Patent and Trademark Office (USPTO)
July 16, 2020
· 3 min read